Chemoprevention use after TNBC ‘may be reasonable’
Research indicates that women with triple-negative breast cancer might benefit from low-dose tamoxifen to reduce the risk of recurrent or new primary disease.
Day: March 31, 2025
Research indicates that women with triple-negative breast cancer might benefit from low-dose tamoxifen to reduce the risk of recurrent or new primary disease.
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.